Patricia Dauer

Also affiliated with Sepragen Corporation (United States)

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Whole transcriptomic analysis of HR+ breast cancer in Black women classified as basal-type by BluePrint.”.

Whole transcriptomic analysis of HR+ breast cancer in Black women classified as basal-type by BluePrint.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.517

N/A

0DataRank · unranked

2 citations

Tuya Pal, Xiao‐Ou Shu, Ann Tezak, Kent Hoskins, Dipali Sharma +9 more

Bioflavonoid luteolin prevents sFlt ‐1 release via HIF ‐1α inhibition in cultured human placenta

The FASEB Journal(2023)10.1096/fj.202300611r

N/A

0DataRank · unranked

15 citations

Chun-yi Chiang, Augustine Rajakumar, Frank T. Spradley, Patricia Dauer, Joey P. Granger +2 more

Impact of race on BluePrint genomic subtyping in HER2+ breast cancer.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.564

N/A

0DataRank · unranked

0 citations

Tuya Pal, Xiao‐Ou Shu, Lindsay Venton, Jennifer G. Whisenant, Kent Hoskins +9 more